| Development of cytarabine prodrugs and delivery systems for leukemia treatment. | |
| | |
MedLine Citation:
|
PMID: 20964588 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Importance of the field: Cytarabine is a polar nucleoside drug used for the treatment of myeloid leukemia and non-Hodgkin's lymphoma. The drug has a short plasma half-life, low stability and limited bioavailability. Overdosing of patients with continuous infusions may lead to side effects. Thus, various prodrug strategies and delivery systems have been explored extensively to enhance the half-life, stability and delivery of cytarabine. Among the recent cytarabine prodrugs, amino acid conjugate ValCytarabine and fatty acid derivative CP-4055 (in Phase III trials) have been investigated for the treatment of leukemia and solid tumors, respectively. Alternatively, delivery systems of cytarabine have emerged for the treatment of different cancers. The liposomal-cytarabine formulation (DepoCyt, Pacira Pharmaceuticals Inc., New Jersey, USA) has been approved for the treatment of lymphomatous meningitis. Areas covered in this review: Various prodrug strategies evaluated for cytarabine are discussed. Then, the review summarizes the drug delivery systems that have been used for more effective cancer therapy. What the reader will gain: This review provides in-depth discussion of the prodrug strategy and delivery systems of cytarabine derivatives for the treatment of cancer. The design of cytarabine prodrugs and delivery systems provides insights for designing the next generation of more effective anticancer agents with enhanced delivery and stability. Take home message: Strategies on designing cytarabine prodrug and delivery formulations showed great promise in developing effective anticancer agents with better therapeutic profile. Similar studies with other anticancer nucleosides can be an alternative approach to gaining access to more effective anticancer agents. |
| | |
Authors:
|
Bhupender S Chhikara; Keykavous Parang |
Related Documents
:
|
20112968 - Host-guest interaction mediated polymeric assemblies: multifunctional nanoparticles for... 17630918 - Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. 2141478 - Nitrosoureas from chemist to physician: classification and recent approaches to drug de... 19413458 - Tight junction modulator and drug delivery. 19446158 - Gastroprotective drugs in australia: utilization patterns between 1997 and 2006 in rela... 11888978 - Corticosteroids and cardiopulmonary bypass : a review of clinical investigations. |
Publication Detail:
|
Type: Journal Article Date: 2010-10-22 |
Journal Detail:
|
Title: Expert opinion on drug delivery Volume: 7 ISSN: 1744-7593 ISO Abbreviation: Expert Opin Drug Deliv Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-12-01 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101228421 Medline TA: Expert Opin Drug Deliv Country: England |
Other Details:
|
Languages: eng Pagination: 1399-414 Citation Subset: IM |
Affiliation:
|
University of Rhode Island, College of Pharmacy, Department of Biomedical and Pharmaceutical Sciences, 41 Lower College Road, Kingston, RI 02881, USA +1 401 874 4471 ; +1 401 874 5787 ; kparang@uri.edu. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Erythrocyte membrane AChE, Na(+), K(+)-ATPase and Mg(2+) ATPase activities in mothers and their prem...
Next Document: Maturational constraints on the recruitment of early processes for syntactic processing.